Alliance Pharma (APH) Hits New 1-Year High at $63.50

Alliance Pharma plc (LON:APH) hit a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 63.50 ($0.85) and last traded at GBX 62.75 ($0.84), with a volume of 202329 shares changing hands. The stock had previously closed at GBX 62.50 ($0.84).

A number of brokerages have issued reports on APH. FinnCap boosted their target price on shares of Alliance Pharma from GBX 58 ($0.78) to GBX 70 ($0.94) and gave the company a “buy” rating in a report on Tuesday, December 12th. Numis Securities reissued a “buy” rating and set a GBX 66 ($0.88) target price (down previously from GBX 71 ($0.95)) on shares of Alliance Pharma in a report on Friday, December 1st. N+1 Singer reissued a “not rated” rating on shares of Alliance Pharma in a report on Wednesday, September 13th. Finally, Investec began coverage on shares of Alliance Pharma in a report on Wednesday, September 13th. They set a “buy” rating and a GBX 59 ($0.79) target price on the stock.

The stock has a market capitalization of $297.63 and a PE ratio of 1,255.00.

TRADEMARK VIOLATION WARNING: “Alliance Pharma (APH) Hits New 1-Year High at $63.50” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at

About Alliance Pharma

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.

What are top analysts saying about Alliance Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alliance Pharma and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit